Latest Adderall Stories

Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%

2010-02-19 06:07:00

DUBLIN, February 19, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the year to December 31, 2009. Financial Highlights Full Year 2009(1) Q4 2009(1) Product sales $2,694 million -2% $777 million +10% Product sales from core products(2) $2,067 million +25% $585 million +36% Total revenues...

Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic

2009-12-02 06:00:00

PHILADELPHIA, Pennsylvania, December 2 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled the litigation with Teva Pharmaceuticals USA, Inc. ("Teva") over Shire's supply to Teva of an authorized generic version of ADDERALL XR. Shire has been supplying Teva with authorized generic ADDERALL XR since April 1, 2009. Shire's ability to supply the product had been limited by restrictions that the US Drug...

Reportlinker Adds Chinese Markets for Central Nervous System Disorder Drugs

2009-11-05 10:42:00

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Central Nervous System Disorder Drugs http://www.reportlinker.com/p0157403/Chinese-Markets-for-Central-Nervous-System-Disorder-Drugs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire China's demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next five years, both production...

Shire Continues to Deliver Excellent Growth From Core Products

2009-10-30 08:12:00

DUBLIN, October 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009. Q3 2009 Financial Highlights Q3 2009(1) Product sales $603 million -15% Product sales from core products(2) $532 million +20% Product sales growth from...

New Study on Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII Shows Administration of Vyvanse Through Two Different Routes Demonstrated a Similar Pharmacokinetic Profile

2009-10-22 14:57:00

PHILADELPHIA, Oct. 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, VyvanseÂ® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. Specifically, the overall rate...

Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)

2009-10-13 11:06:00

PHILADELPHIA, October 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. ("Sandoz") in connection with Sandoz's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder. The settlement also provides Sandoz with...

Celebrity Dancer, Karina Smirnoff, Speaks Out for the First Time on How ADHD Has Impacted Her Life

2009-09-16 07:00:00

NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- In recognition of national ADHD Awareness Day, "Dancing with the Stars" performer and professional dancer, Karina Smirnoff, is adding her voice to the growing attention about adult Attention-Deficit/Hyperactivity Disorder (ADHD) by sharing her personal experiences for the first time and advocating for others to seek evaluation and appropriate treatment. Karina is partnering with Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

2009-08-05 07:30:00

DUBLIN, August 5 /PRNewswire-FirstCall/ -- - 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009. Q2 2009 Financial Highlights Q2 2009(1) Product sales $558 million -21% Product sales (excluding ADDERALL XR) $491 million...

Vyvanse CII Significantly Improved ADHD Symptoms For Children 13 Hours After Administration

2009-07-22 17:15:00

Vyvanse first oral ADHD stimulant with published data demonstrating significant ADHD symptom improvement from 1.5 hours up to 13 hours after administration in childrenShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily VyvanseÂ® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

2009-07-22 08:00:00

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last...